Novo Nordisk is pumping up its heart failure plans. The drugmaker, swelled by its GLP-1 windfall, has decided to buy Cardior Pharmaceuticals and
Nick Paul Taylor is a freelance pharmaceutical and biotech writer, contributing to various publications such as Biotech, Med Tech News, Yahoo Finance, and Fierce Pharma. With a focus on the pharmaceutical and biotech industry, Nick covers topics including drug launches, clinical trials, regulatory affairs, and industry developments. His work has also been featured in Healthcare Dive, The Science Advisory Board, BioPharma Dive, and other industry publications.